Makoto Naganuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Makoto Naganuma has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Takanori Kanai
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
7 shared publications Haruhiko Ogata
Cancer Center, Keio University, Tokyo, Japan
4 shared publicationsKenji Watanabe
Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan
4 shared publications- Shinta Mizuno
Gastroenterology and Hepatology, Keio Universtity Hospital, Shinjyuku, Tokyo, Japan
4 shared publications Yasushi Iwao
4 shared publicationsYoshihiro Nakazato
4 shared publications
Latest Publications
- Open Access
- 2 January 2019
- Published by Taylor & Francis in Immunological Medicine
- Vol. 42 (1) , 16-21
Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases
Indigo naturalis (IN) is a herbal medicine extracted from leaves and stems of plants and is a component of crude drugs used in China. Recently, IN was reported to be effective for treating (UC) and psoriasis. The mechanisms of IN for UC is not clear, but aryl hydrocarbon receptor ligand, the active components of IN, can promote mucosal healing by inducing the production of interleukin-22 from type-3 innate lymphocytes cells. Although IN is effective even for refractory cases, critical adverse effects including IN-induced colitis and pulmonary arterial hypertension should be concerned. Due to adverse effects of IN, topical treatment of IN is useful for distal UC as well as psoriasis to secure patients’ safeties. Many refractory patients may be helped by IN if it becomes available in appropriate forms for clinical practice. In the near future, the mechanism that underlies the adverse effects of IN needs to be determined, and extraction of active ingredients with fewer side effects, investigated.
- 2 January 2019
- Published by Taylor & Francis in Immunological Medicine
- Vol. 42 (1) , 16-21
Open AccessTreatment with indigo naturalis for inflammatory bowel disease and other immune diseases
Indigo naturalis (IN) is a herbal medicine extracted from leaves and stems of plants and is a component of crude drugs used in China. Recently, IN was reported to be effective for treating (UC) and psoriasis. The mechanisms of IN for UC is not clear, but aryl hydrocarbon receptor ligand, the active components of IN, can promote mucosal healing by inducing the production of interleukin-22 from type-3 innate lymphocytes cells. Although IN is effective even for refractory cases, critical adverse effects including IN-induced colitis and pulmonary arterial hypertension should be concerned. Due to adverse effects of IN, topical treatment of IN is useful for distal UC as well as psoriasis to secure patients’ safeties. Many refractory patients may be helped by IN if it becomes available in appropriate forms for clinical practice. In the near future, the mechanism that underlies the adverse effects of IN needs to be determined, and extraction of active ingredients with fewer side effects, investigated.
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB295
Su1247 CLINICAL UTILITY OF ULTRA-THIN SINGLE-BALLOON ENTEROSCPY; A FEASIBILITY STUDY
- 1 June 2018
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 87 (6) , AB295
Su1247 CLINICAL UTILITY OF ULTRA-THIN SINGLE-BALLOON ENTEROSCPY; A FEASIBILITY STUDY
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1944 - Intestinal Dysbiosis Induces Systemic Dysregulation of Biotin Metabolism, Resulting in Extraintestinal Manifestation
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Su1944 - Intestinal Dysbiosis Induces Systemic Dysregulation of Biotin Metabolism, Resulting in Extraintestinal Manifestation
- 13 October 2017
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (4) , 579-581
Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
In Fig. 2(c) of this article, the length of the “95% CI difference bars” under the items labelled “Left-sided and Pancolitis” and “Left-sided” under the heading “Disease type” was corrected. The...
- 13 October 2017
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (4) , 579-581
Correction to: Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
In Fig. 2(c) of this article, the length of the “95% CI difference bars” under the items labelled “Left-sided and Pancolitis” and “Left-sided” under the heading “Disease type” was corrected. The...
- Open Access
- 4 August 2017
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (4) , 494-506
Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
Background Budesonide foam is used for the topical treatment of distal ulcerative colitis. This phase III study was performed to confirm mucosal healing and other therapeutic effects of twice-daily budesonide 2-mg foam in patients with mild-to-moderate ulcerative colitis including left-sided colitis and pancolitis. Methods This was a multicenter, randomized, placebo-controlled, double-blind trial. A total of 126 patients with mild-to-moderate ulcerative colitis with active inflammation in the distal colon were randomized to two groups receiving twice-daily budesonide 2 mg/25 ml foam or placebo foam. The primary endpoint was the percentage of complete mucosal healing of distal lesions (endoscopic subscore of 0) at week 6. Some patients continued the treatment through week 12. Drug efficacy and safety were evaluated. Results The percentages of both complete mucosal healing of distal lesions and clinical remission were significantly improved in the budesonide as compared with the placebo group (p = 0.0003 and p = 0.0035). Subgroup analysis showed similar efficacy of budesonide foam for complete mucosal healing of distal lesions and clinical remission regardless of disease type. The clinical remission percentage tended to be higher in patients achieving complete mucosal healing of distal lesions than in other patients. There were no safety concerns with budesonide foam. Conclusions This study confirmed for the first time complete mucosal healing with twice-daily budesonide 2-mg foam in mild-to-moderate ulcerative colitis with distal active inflammation. The results also indicated that complete mucosal healing of distal lesions by budesonide foam promotes clinical remission of ulcerative colitis. Clinical trial registration no.: Japic CTI-142704.
- 4 August 2017
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 53 (4) , 494-506
Open AccessComplete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
Background Budesonide foam is used for the topical treatment of distal ulcerative colitis. This phase III study was performed to confirm mucosal healing and other therapeutic effects of twice-daily budesonide 2-mg foam in patients with mild-to-moderate ulcerative colitis including left-sided colitis and pancolitis. Methods This was a multicenter, randomized, placebo-controlled, double-blind trial. A total of 126 patients with mild-to-moderate ulcerative colitis with active inflammation in the distal colon were randomized to two groups receiving twice-daily budesonide 2 mg/25 ml foam or placebo foam. The primary endpoint was the percentage of complete mucosal healing of distal lesions (endoscopic subscore of 0) at week 6. Some patients continued the treatment through week 12. Drug efficacy and safety were evaluated. Results The percentages of both complete mucosal healing of distal lesions and clinical remission were significantly improved in the budesonide as compared with the placebo group (p = 0.0003 and p = 0.0035). Subgroup analysis showed similar efficacy of budesonide foam for complete mucosal healing of distal lesions and clinical remission regardless of disease type. The clinical remission percentage tended to be higher in patients achieving complete mucosal healing of distal lesions than in other patients. There were no safety concerns with budesonide foam. Conclusions This study confirmed for the first time complete mucosal healing with twice-daily budesonide 2-mg foam in mild-to-moderate ulcerative colitis with distal active inflammation. The results also indicated that complete mucosal healing of distal lesions by budesonide foam promotes clinical remission of ulcerative colitis. Clinical trial registration no.: Japic CTI-142704.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S409
Maintenance Therapy with Lower Dose 5-Aminosalicylate Increases the Clinical Relapse in Patients with Ulcerative Colitis who had Previous Use of Corticosteroids
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S409
Maintenance Therapy with Lower Dose 5-Aminosalicylate Increases the Clinical Relapse in Patients with Ulcerative Colitis who had Previous Use of Corticosteroids
- Open Access
- 20 January 2017
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 05 (01) , E76-E82
Evaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels
Background and study aims Colonoscopies can predict long-term prognoses in patients with ulcerative colitis (UC). Recently, a new imaging technology has been developed that uses 3 types of illumination with center wavelengths of 540 nm, 600 nm, and 630 nm. The use of both the 600-nm and 630-nm lights (Dual red imaging; DRI) is critical for identifying blood vessels in deeper tissue. The aim of this study was to evaluate the usefulness of DRI for assessing the severity of inflammation in patients with UC. Patients and methods A total of 43 UC patients were retrospectively enrolled to evaluate the endoscopic severity of 112 colon segments, and Mayo endoscopic scores, DRI scores and the severity of inflammation on a visual analogue scale (VAS) were compared. The Mayo endoscopic scores, DRI scores, and histologic scores were evaluated, and the interobserver agreement on DRI scores among 5 investigators was also assessed. The usefulness of DRI scores for predicting prognoses was also assessed in patients with clinical remission. Results The DRI scores were closely correlated with the VAS for the severity of colonic inflammation (r = 0.96) and the histologic scores (r = 0.72 – 0.8). The DRI scores had a higher rate of interobserver agreement (κ values = 0.63 – 0.88) than the Mayo endoscopic scores (κ values = 0.44 – 0.59). Inter-observer agreement between 4 non-experts was also excellent (mean κ value = 0.76, range 0.63 – 0.82). The expected time until recurrence was significantly longer in patients with lower DRI scores (P < 0.01). Conclusion DRI can be used in patients with mild to moderate endoscopic severity because it targets the deep vascular pattern. The prognosis of UC can be predicted by assessing deep vessels using DRI.
- 20 January 2017
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 05 (01) , E76-E82
Open AccessEvaluation of the severity of ulcerative colitis using endoscopic dual red imaging targeting deep vessels
Background and study aims Colonoscopies can predict long-term prognoses in patients with ulcerative colitis (UC). Recently, a new imaging technology has been developed that uses 3 types of illumination with center wavelengths of 540 nm, 600 nm, and 630 nm. The use of both the 600-nm and 630-nm lights (Dual red imaging; DRI) is critical for identifying blood vessels in deeper tissue. The aim of this study was to evaluate the usefulness of DRI for assessing the severity of inflammation in patients with UC. Patients and methods A total of 43 UC patients were retrospectively enrolled to evaluate the endoscopic severity of 112 colon segments, and Mayo endoscopic scores, DRI scores and the severity of inflammation on a visual analogue scale (VAS) were compared. The Mayo endoscopic scores, DRI scores, and histologic scores were evaluated, and the interobserver agreement on DRI scores among 5 investigators was also assessed. The usefulness of DRI scores for predicting prognoses was also assessed in patients with clinical remission. Results The DRI scores were closely correlated with the VAS for the severity of colonic inflammation (r = 0.96) and the histologic scores (r = 0.72 – 0.8). The DRI scores had a higher rate of interobserver agreement (κ values = 0.63 – 0.88) than the Mayo endoscopic scores (κ values = 0.44 – 0.59). Inter-observer agreement between 4 non-experts was also excellent (mean κ value = 0.76, range 0.63 – 0.82). The expected time until recurrence was significantly longer in patients with lower DRI scores (P < 0.01). Conclusion DRI can be used in patients with mild to moderate endoscopic severity because it targets the deep vascular pattern. The prognosis of UC can be predicted by assessing deep vessels using DRI.
- 23 August 2016
- Published by Springer Nature in Abdominal Radiology
- Vol. 42 (1) , 141-151
Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn’s disease in patients treated with anti-TNF treatment
MR enterography (MRE) is useful for evaluating transmural lesions and extra-intestinal complications of Crohn’s disease (CD). The aim of this study was to prospectively evaluate whether MRE could detect severe strictures and inflammatory lesions in patients who lost the responsiveness to anti-TNF treatment and whether MRE could predict prognosis of CD patients with clinical remission. MRE were conducted in 50 patients who were treated with infliximab or adalimumab. The main aims of this study were as follows; (1) to compare the rates of CD lesions of the patients with clinical remission and active disease at the baseline and (2) to assess the MRE findings that were predictors of clinical recurrence among patients with clinical remission at the baseline. The MRE detection rates of markedly increased contrast uptake, severe strictures, and the presence of ulcers were significantly higher in patients with Crohn Disease Activity Index ≥150 than in patients with clinical remission. Over a mean follow-up of 18.2 months, the absence of ulceration (p = 0.001) or severe stricture (p = 0.01) prolonged clinical recurrence among patients with clinical remission at baseline. Expected duration of recurrence significantly prolonged in patients with total magnetic resonance index of activity (MaRIA) <36.3 [29.8 months (95% CI 23.7–35.9)] than in patients with total MaRIA ≥36.3 (13.9 months (95% CI 7.7–20.1). A cut-off value of total MaRIA score of 36.3 had a sensitivity of 75% and specificity of 70% for predicting recurrence. Findings of ulceration and severe stricture on MRE predict prognosis of CD patients who were treated with anti-TNF treatment. MRE might be useful for making treatment decisions in patients who lost the effectiveness of medical treatments.
- 23 August 2016
- Published by Springer Nature in Abdominal Radiology
- Vol. 42 (1) , 141-151
Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn’s disease in patients treated with anti-TNF treatment
MR enterography (MRE) is useful for evaluating transmural lesions and extra-intestinal complications of Crohn’s disease (CD). The aim of this study was to prospectively evaluate whether MRE could detect severe strictures and inflammatory lesions in patients who lost the responsiveness to anti-TNF treatment and whether MRE could predict prognosis of CD patients with clinical remission. MRE were conducted in 50 patients who were treated with infliximab or adalimumab. The main aims of this study were as follows; (1) to compare the rates of CD lesions of the patients with clinical remission and active disease at the baseline and (2) to assess the MRE findings that were predictors of clinical recurrence among patients with clinical remission at the baseline. The MRE detection rates of markedly increased contrast uptake, severe strictures, and the presence of ulcers were significantly higher in patients with Crohn Disease Activity Index ≥150 than in patients with clinical remission. Over a mean follow-up of 18.2 months, the absence of ulceration (p = 0.001) or severe stricture (p = 0.01) prolonged clinical recurrence among patients with clinical remission at baseline. Expected duration of recurrence significantly prolonged in patients with total magnetic resonance index of activity (MaRIA) <36.3 [29.8 months (95% CI 23.7–35.9)] than in patients with total MaRIA ≥36.3 (13.9 months (95% CI 7.7–20.1). A cut-off value of total MaRIA score of 36.3 had a sensitivity of 75% and specificity of 70% for predicting recurrence. Findings of ulceration and severe stricture on MRE predict prognosis of CD patients who were treated with anti-TNF treatment. MRE might be useful for making treatment decisions in patients who lost the effectiveness of medical treatments.
- 18 May 2016
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (11) , 1303-1309
The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission
Background The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is a validated scoring system. Nevertheless, few studies have investigated its usefulness in clinical settings. In this study, we aimed to predict the clinical prognosis of patients with ulcerative colitis (UC) in clinical remission using the UCEIS. Methods A total of 285 UC patients who underwent a colonoscopy between April 2012 and March 2013 were enrolled. We reviewed clinical characteristics and endoscopic scores at the time of the colonoscopy and checked the clinical remission rate of the patients through September 2015. Clinical remission and recurrence were defined as a partial Mayo of ≤1 and ≥3, respectively. Results UCEIS was strongly correlated with the Mayo endoscopic score (r=0.93), moderately correlated with clinical severity (r=0.64), and mildly correlated with C-reactive protein (r=0.34). The recurrence rate increased gradually as it became more endoscopically severe (5.0% for UCEIS=0, 22.4% for UCEIS=1, 27.0% for UCEIS=2, 35.7% for UCEIS=3, and 75.0% for UCEIS=4-5) in patients with clinical remission. UCEIS and the concomitant use of thiopurine were independent factors predicting clinical recurrence. A multivariate analysis indicated that the absence of bleeding (pConclusion The UCEIS is useful to predict the medium to long-term outcomes of UC patients with clinical remission. The absence of bleeding or mucosal damage is important for maintaining clinical remission.
- 18 May 2016
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 10 (11) , 1303-1309
The Ulcerative Colitis Endoscopic Index of Severity is Useful to Predict Medium- to Long-Term Prognosis in Ulcerative Colitis Patients with Clinical Remission
Background The Ulcerative Colitis Endoscopic Index of Severity (UCEIS) is a validated scoring system. Nevertheless, few studies have investigated its usefulness in clinical settings. In this study, we aimed to predict the clinical prognosis of patients with ulcerative colitis (UC) in clinical remission using the UCEIS. Methods A total of 285 UC patients who underwent a colonoscopy between April 2012 and March 2013 were enrolled. We reviewed clinical characteristics and endoscopic scores at the time of the colonoscopy and checked the clinical remission rate of the patients through September 2015. Clinical remission and recurrence were defined as a partial Mayo of ≤1 and ≥3, respectively. Results UCEIS was strongly correlated with the Mayo endoscopic score (r=0.93), moderately correlated with clinical severity (r=0.64), and mildly correlated with C-reactive protein (r=0.34). The recurrence rate increased gradually as it became more endoscopically severe (5.0% for UCEIS=0, 22.4% for UCEIS=1, 27.0% for UCEIS=2, 35.7% for UCEIS=3, and 75.0% for UCEIS=4-5) in patients with clinical remission. UCEIS and the concomitant use of thiopurine were independent factors predicting clinical recurrence. A multivariate analysis indicated that the absence of bleeding (pConclusion The UCEIS is useful to predict the medium to long-term outcomes of UC patients with clinical remission. The absence of bleeding or mucosal damage is important for maintaining clinical remission.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S997
Tu1983 The Investigation of Medium- to Long-Term Prognosis of Ulcerative Colitis Patients Using Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S997
Tu1983 The Investigation of Medium- to Long-Term Prognosis of Ulcerative Colitis Patients Using Ulcerative Colitis Endoscopic Index of Severity (UCEIS)